human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
Metastatic Solid Tumor
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 65/ 100
Competitive context
131 Active assets in the Metastatic Solid Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Cyclophosphamide InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Epirubicin InSilico Medicine Hong Kong Limited | Phase 2 | CCC |
Nivolumab Lantern Pharma Inc. | Phase 2 | CCC |
Trastuzumab Emtansine M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 50 →
Same molecule, other indications
human T-lymphocyte activation antigen CD80 (activation B7-1 antigen, CTLA-4 counter-receptor B7.1, CD80) extracellular domain containing fragment (1-208 in the current sequence) fused via peptide linker <sup>209</sup>GSGGGGSGGGGSGGGGS<sup>225</sup> to an Fc fragment of human immunoglobulin G4 (226-454) [Homo sapiens IGHG4*01, hinge ins<sup>226</sup>>A, S<sup>236</sup>>P (226-238), CH2 F<sup>242</sup>>A, L<sup>243</sup>>A, T<sup>258</sup>>Q (239-348), CH3 M<sup>436</sup>>L (349-453), CHS K<sup>455</sup>>del (454)] fused via peptide/ linker <sup>455</sup>GGGGS<sup>459</sup> to human interleukin-2 (IL-2, T-cell growth factor (TCGF)) (1-133, 460-592 in the current sequence), variant (R<sup>38</sup>>A<sup>497</sup>, F<sup>42</sup>>A<sup>501</sup>), dimer (234-234', 237-237')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →